

line 29, after the paragraph ending "Table 4.", insert Table 4 from page 27.

Page 24, line 18, after the paragraph ending "protective activity.", insert Table 5 from page 28.

Page 26, delete Tables 1 and 2 and move to page 23, after line 17.

Page 27, delete Tables 3 and 4 and move to page 23, after lines 23 and 29, respectively.

Page 28, delete Table 5 and move to page 24, after line 18.

IN THE CLAIMS

Please rewrite claims 1, 2 and 6 in once-amended form as follows:

1 (Amended). A hybrid protein comprising two coexpressed amino acid sequences forming a dimer, each comprising:

(a) at least one amino acid sequence selected from the group consisting of a homomeric receptor, a chain of a heteromeric receptor, a ligand, [and fragments thereof] a fragment of said receptors, each of which [retain] retains the ligand-receptor binding capability, an antibody light or heavy chain, a combination of antibody light and heavy chains, and a fragment of an antibody chain or combined antibody chains; and

(b) a subunit of a heterodimeric proteinaceous hormone, or [fragment] a fragment thereof which [retain] retains the ability of the subunit to form a heterodimer with other subunits thereof;

wherein sequences (a) and (b) are [bonded] joined
either directly or through a peptide linker, and in which the
[sequence] sequences (b) in each of said two coexpressed
sequences are capable of aggregating to form a dimer complex.

2 (Amended). A hybrid protein in accordance with
claim 1, wherein said sequence (a) is selected from the group
consisting of TNF Binding Protein 1 (TBP1), TNF Binding Protein
2 (TBP2) or [fragments thereof] a fragment of said TBP1 or TBP2
still containing the ligand binding domain; the extracellular
domain of the $IFN\alpha/\beta$ receptor or the $IFN\gamma$ receptor; a
gonadotropin receptor or extracellular fragments thereof;
antibody light chains or fragments thereof, optionally
associated with the respective heavy chains; antibody heavy
chains or fragments thereof, optionally associated with the
respective light chains; antibody Fab domains; and IL-6, $IFN\beta$,
TPO or fragments thereof.

6 (Amended). A hybrid protein in accordance with
claim 1, wherein said two coexpressed amino acid sequences each
include the sequence for TBP1 or [the] a fragment thereof having
a sequence corresponding to amino acid residues 20-161 or 20-190
of TBP1, as sequence (a) and the respective α and β subunits
of hCG or fragments thereof, as sequence (b), wherein said two
coexpressed amino acid sequences form a dimer complex through
association of said α and β subunits of hCG or fragments
thereof.

Claim 4, line 2, delete "linked" and insert therefor
--joined--.